Nutex Health Statistics
Total Valuation
Nutex Health has a market cap or net worth of $917.73 million. The enterprise value is $1.05 billion.
| Market Cap | 917.73M |
| Enterprise Value | 1.05B |
Important Dates
The last earnings date was Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nutex Health has 6.88 million shares outstanding. The number of shares has increased by 17.75% in one year.
| Current Share Class | 6.88M |
| Shares Outstanding | 6.88M |
| Shares Change (YoY) | +17.75% |
| Shares Change (QoQ) | +1.53% |
| Owned by Insiders (%) | 31.57% |
| Owned by Institutions (%) | 35.09% |
| Float | 4.30M |
Valuation Ratios
The trailing PE ratio is 9.62 and the forward PE ratio is 6.22.
| PE Ratio | 9.62 |
| Forward PE | 6.22 |
| PS Ratio | 1.04 |
| Forward PS | 1.01 |
| PB Ratio | 2.66 |
| P/TBV Ratio | 2.93 |
| P/FCF Ratio | 3.45 |
| P/OCF Ratio | 3.35 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.55, with an EV/FCF ratio of 3.98.
| EV / Earnings | 10.94 |
| EV / Sales | 1.20 |
| EV / EBITDA | 2.55 |
| EV / EBIT | 2.68 |
| EV / FCF | 3.98 |
Financial Position
The company has a current ratio of 3.14, with a Debt / Equity ratio of 0.79.
| Current Ratio | 3.14 |
| Quick Ratio | 3.00 |
| Debt / Equity | 0.79 |
| Debt / EBITDA | 0.83 |
| Debt / FCF | 1.32 |
| Interest Coverage | 18.92 |
Financial Efficiency
Return on equity (ROE) is 53.65% and return on invested capital (ROIC) is 51.55%.
| Return on Equity (ROE) | 53.65% |
| Return on Assets (ROA) | 28.59% |
| Return on Invested Capital (ROIC) | 51.55% |
| Return on Capital Employed (ROCE) | 50.88% |
| Weighted Average Cost of Capital (WACC) | 12.52% |
| Revenue Per Employee | $875,575 |
| Profits Per Employee | $95,900 |
| Employee Count | 1,005 |
| Asset Turnover | 1.02 |
| Inventory Turnover | 111.54 |
Taxes
In the past 12 months, Nutex Health has paid $57.81 million in taxes.
| Income Tax | 57.81M |
| Effective Tax Rate | 23.11% |
Stock Price Statistics
The stock price has decreased by -1.66% in the last 52 weeks. The beta is 2.06, so Nutex Health's price volatility has been higher than the market average.
| Beta (5Y) | 2.06 |
| 52-Week Price Change | -1.66% |
| 50-Day Moving Average | 116.97 |
| 200-Day Moving Average | 120.58 |
| Relative Strength Index (RSI) | 56.97 |
| Average Volume (20 Days) | 124,989 |
Short Selling Information
The latest short interest is 916,308, so 13.32% of the outstanding shares have been sold short.
| Short Interest | 916,308 |
| Short Previous Month | 996,714 |
| Short % of Shares Out | 13.32% |
| Short % of Float | 21.31% |
| Short Ratio (days to cover) | 4.82 |
Income Statement
In the last 12 months, Nutex Health had revenue of $879.95 million and earned $96.38 million in profits. Earnings per share was $13.86.
| Revenue | 879.95M |
| Gross Profit | 445.10M |
| Operating Income | 393.23M |
| Pretax Income | 250.13M |
| Net Income | 96.38M |
| EBITDA | 414.16M |
| EBIT | 393.23M |
| Earnings Per Share (EPS) | $13.86 |
Balance Sheet
The company has $207.35 million in cash and $349.09 million in debt, with a net cash position of -$141.74 million or -$20.60 per share.
| Cash & Cash Equivalents | 207.35M |
| Total Debt | 349.09M |
| Net Cash | -141.74M |
| Net Cash Per Share | -$20.60 |
| Equity (Book Value) | 442.05M |
| Book Value Per Share | 49.81 |
| Working Capital | 395.21M |
Cash Flow
In the last 12 months, operating cash flow was $272.68 million and capital expenditures -$7.98 million, giving a free cash flow of $264.70 million.
| Operating Cash Flow | 272.68M |
| Capital Expenditures | -7.98M |
| Depreciation & Amortization | 20.93M |
| Net Borrowing | -23.69M |
| Free Cash Flow | 264.70M |
| FCF Per Share | $38.47 |
Margins
Gross margin is 50.58%, with operating and profit margins of 44.69% and 10.95%.
| Gross Margin | 50.58% |
| Operating Margin | 44.69% |
| Pretax Margin | 28.42% |
| Profit Margin | 10.95% |
| EBITDA Margin | 47.07% |
| EBIT Margin | 44.69% |
| FCF Margin | 30.08% |
Dividends & Yields
Nutex Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.75% |
| Shareholder Yield | -17.75% |
| Earnings Yield | 10.56% |
| FCF Yield | 29.01% |
Analyst Forecast
The average price target for Nutex Health is $235.50, which is 76.58% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $235.50 |
| Price Target Difference | 76.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 3.14% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 3, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 3, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Nutex Health has an Altman Z-Score of 3.28 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.28 |
| Piotroski F-Score | 5 |